July 29, 2020
PA-20-260 - PHS 2020 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
PA-20-261 - PHS 2020-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required)
PA-20-262 - PHS 2020-2 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required)
PA-20-265 - PHS 2020-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)
National Center for Complementary and Integrative Health (NCCIH)
The purpose of this Notice is to revise the NCCIH policy for budget and duration for SBIR and STTR Phase I and Phase II applications submitted in response to the following Funding Opportunity Announcements (FOAs) and subsequent reissued versions of these FOAs: PA-20-260, PA-20-261, PA-20-262, PA-20-265.
For budgetary, administrative, or programmatic reasons, NCCIH may decide not to fund an application or may decrease the length of an award and/or the budget recommended by a review committee.
Through this Notice, NCCIH has revised its budget and duration policies for SBIR/STTR Phase I and Phase II applications. Generally, NCCIH will not fund:
These total award amounts will be adjusted according to the NIH guidelines.
For "National Institutes of Health SBA-Approved SBIR/STTR Topics for Awards over Statutory Budget Limitations," the Small Business Administration (SBA) has approved an NIH SBIR/STTR Topic Waiver list for which NCCIH generally will not fund:
Merav Sabri, Ph.D.
National Center for Complementary and Integrative Health (NCCIH)
Phone: 301-496-2583;
Email: merav.sabri@nih.gov